LATENT AUTOIMMUNE DIABETES IN ADULTS

✓ Medically ReviewedDISEASEID: MDBT0263🚨 TRIAGE: URGENTICD-10: E13.65

📖

Definition

CLINICAL DEFINITION

Latent autoimmune diabetes in adults (LADA) is a slowly progressive form of autoimmune diabetes characterised by adult-onset hyperglycaemia, the presence of circulating islet autoantibodies (most commonly glutamic acid decarboxylase 65 [GAD65] autoantibodies), and an initial period of insulin independence for at least 6 months after diagnosis. It sits on a continuum between classic type 1 diabetes and type 2 diabetes, sharing autoimmune features with the former and variable insulin resistance with the latter. The widely used Immunology of Diabetes Society criteria require age >30 years at diagnosis, positivity for at least one islet autoantibody, and no insulin requirement for the first 6 months.

IN PLAIN ENGLISH

LADA is a form of diabetes that develops in adults and is caused by the immune system slowly damaging the insulin-producing cells of the pancreas. At first, it looks like type 2 diabetes and does not need insulin, but over months or years the pancreas produces less insulin, and most people eventually need insulin treatment.

COMMON MISCONCEPTION / WHAT IT DOES NOT MEAN

LADA is NOT type 2 diabetes, even though it often presents with a similar adult-onset pattern and may initially respond to oral glucose-lowering agents. It is also NOT classic type 1 diabetes, because the autoimmune destruction of pancreatic beta cells is slower and insulin is not required at diagnosis. The term should not be applied to adults with autoimmune diabetes who require insulin within the first 6 months, as that presentation is classified as adult-onset type 1 diabetes.

🔤

Word Breakdown

diabetes

=From Greek 'diabētēs' — a siphon, referring to the passage of large volumes of urine; 'mellitus' means honey-sweet

Literal Meaning: A condition of excessive urine flow, with the modifying descriptors indicating a latent, immune-mediated form occurring in adults

🏷️

Abbreviations

LADA=Latent Autoimmune Diabetes in Adults — the standard acronym for this slowly progressive form of autoimmune diabetes

🔄

Synonyms & Variants

Type 1.5 Diabetes›Slowly Evolving Immune-mediated Diabetes of Adult (SEIDA)›

🎯

Category-Specific Context

LADA is a disease category that bridges autoimmune type 1 diabetes and metabolic type 2 diabetes. It is distinguished from type 1 diabetes by older age at onset and a prolonged period of insulin independence, and from type 2 diabetes by the presence of islet autoantibodies and a more predictable decline in beta-cell function. Recognition matters because management differs from typical type 2 diabetes, particularly regarding the avoidance of sulfonylureas and the anticipation of eventual insulin requirement.

🏥

Clinical Context & Usage

CLINICAL SETTINGS

Endocrinology Outpatient ClinicGeneral Medicine WardPrimary Care ClinicDiabetes Outpatient ClinicInternal Medicine Ward

USAGE & DOCUMENTATION NOTES

In clinical documentation, LADA is often recorded as 'LADA' or 'type 1.5 diabetes' in the assessment, with the supporting autoantibody result (most commonly GAD65) and C-peptide level noted. Referral letters typically state the age at diagnosis, the initial response to oral agents, and the antibody titre, because these features support the classification. When insulin is started, the note usually records the C-peptide level that prompted the change and the insulin regimen chosen. Because LADA is frequently misclassified as type 2 diabetes, the term is used to flag the need for autoimmune monitoring and periodic beta-cell function assessment.

🔬

Primary Causes & Pathophysiology

PATHOPHYSIOLOGY

LADA arises from a slowly progressive T-cell-mediated autoimmune destruction of pancreatic beta cells, superimposed on a variable background of insulin resistance. The process begins with loss of self-tolerance to islet antigens, particularly glutamic acid decarboxylase 65 (GAD65), leading to lymphocytic infiltration of the islets and gradual beta-cell apoptosis. Because the rate of beta-cell loss is slower than in classic type 1 diabetes, a substantial reserve of insulin secretion remains at diagnosis, which is why hyperglycaemia develops insidiously and insulin is not immediately required. Insulin resistance, often related to adiposity or age-related metabolic changes, increases the demand on the dwindling beta-cell mass and accelerates the clinical manifestation of diabetes. Over time, beta-cell function declines further, C-peptide levels fall, and glycaemic control deteriorates despite oral therapy, eventually necessitating insulin replacement. The heterogeneity of LADA reflects varying contributions of autoimmunity (higher GAD65 titres associated with faster progression) and insulin resistance (associated with a more type 2-like phenotype).

PRIMARY CAUSES

Autoimmune beta-cell destruction

T-cell-mediated targeting of pancreatic beta cells, with GAD65 and other islet autoantibodies as markers, causes progressive insulin secretory failure.

Genetic susceptibility

Overlap between type 1 diabetes–associated HLA haplotypes and type 2 diabetes–associated polymorphisms contributes to the hybrid phenotype.

Insulin resistance

Obesity, ageing, and sedentary lifestyle increase insulin demand, unmasking diabetes earlier in the course of beta-cell decline.

🌍

Epidemiology

Prevalence:LADA accounts for approximately 2–12% of adults diagnosed with diabetes in clinic-based studies, with a pooled global prevalence of about 8.9% among adult-onset diabetic individuals in a 2023 meta-analysis. Prevalence estimates vary substantially by ethnicity, geography, and the autoantibody assay used.

Age Group:Predominantly adults, with the Immunology of Diabetes Society definition requiring onset after age 30 years. The median age at diagnosis is commonly in the fourth to fifth decade, though cases can present at any adult age.

Sex Predilection:Equal

Geographic Distribution:LADA occurs worldwide, but prevalence varies with ethnicity and region. Higher proportions of LADA among adult-onset diabetes have been reported in Northern European and some Middle Eastern populations, while lower proportions are reported in certain East Asian cohorts; differences may reflect genetic background, autoantibody assay methodology, and ascertainment.

Red Flags & Triage ★

TRIAGE LEVEL

🚨 URGENT

DO NOT MISS — LIFE-THREATENING PRESENTATIONS

A lean adult with diabetes and a personal or family history of autoimmune disease — consider LADA and check islet autoantibodies rather than assuming type 2 diabetes, because misclassification delays appropriate therapy and monitoring.
Rapid deterioration of glycaemic control or unexplained weight loss in a patient diagnosed with type 2 diabetes — consider evolving insulin deficiency from LADA and assess C-peptide and ketones, because diabetic ketoacidosis can occur if insulin deficiency becomes severe.

URGENT EVALUATION TRIGGERS

Blood glucose persistently above 13.9 mmol/L (250 mg/dL) with symptoms of polyuria and polydipsia despite oral therapy
Unexplained weight loss or fatigue in a patient with known diabetes
Ketones detected in blood or urine (beta-hydroxybutyrate ≥1.5 mmol/L) — assess for diabetic ketoacidosis
HbA1c rising above the individualized target despite adherence to oral glucose-lowering therapy

Contraindications & Precautions

CONTRAINDICATIONS

Sulfonylureas — these insulin secretagogues are generally avoided in LADA because they may accelerate beta-cell exhaustion and worsen glycaemic control over time

SPECIAL PRECAUTIONS

Monitor C-peptide periodically to detect declining beta-cell function and guide timely insulin initiation
Use SGLT2 inhibitors with caution because of the risk of euglycaemic diabetic ketoacidosis when insulin deficiency is present
Screen for associated autoimmune conditions (e.g.
thyroid disease
coeliac disease) as clinically indicated
Apply the same complication screening schedule as for other forms of diabetes
including retinal
renal
and foot assessments

Complications

DOWNSTREAM CLINICAL COMPLICATIONS

Diabetic retinopathy — microvascular damage to the retina; risk increases with longer disease duration and poorer glycaemic control
and may be higher in LADA than in type 2 diabetes over time
Cardiovascular disease — increased risk of ischaemic heart disease and related mortality
with cohort data suggesting risk comparable to or exceeding that in type 2 diabetes
Diabetic neuropathy — peripheral and autonomic nerve damage
including small-fibre neuropathy
related to chronic hyperglycaemia
Diabetic nephropathy — albuminuria and declining glomerular filtration rate
with registry data indicating prevalence similar to or exceeding that in type 2 diabetes
Diabetic ketoacidosis — a risk when insulin deficiency becomes severe
particularly if insulin therapy is delayed or omitted
or with concurrent SGLT2 inhibitor use

🔀

Confused With (LASA & DDx) ★

LEXICAL (LASA) — SIMILAR NAMES

LADY (Latent Autoimmune Diabetes in the Young)

LADY sounds similar to LADA but refers to autoimmune diabetes with onset before age 18; confusing the two can lead to incorrect age-based classification.

MODY (Maturity-Onset Diabetes of the Young)

MODY is a monogenic form of diabetes that can present in young adults and is often confused with LADA; MODY is characterised by strong family history and absence of islet autoantibodies.

CLINICAL DIFFERENTIAL DIAGNOSES (DDx)

Type 2 Diabetes Mellitus

Key Distinguishing Feature: Type 2 diabetes is typically associated with older age, obesity, metabolic syndrome, negative islet autoantibodies, and normal-to-high C-peptide; LADA is distinguished by autoantibody positivity and a leaner phenotype.

Type 1 Diabetes Mellitus

Key Distinguishing Feature: Classic type 1 diabetes presents with younger age, rapid onset, low C-peptide, and immediate insulin dependence; LADA has a slower course and a prolonged insulin-independent phase.

Maturity-Onset Diabetes of the Young (MODY)

Key Distinguishing Feature: MODY is a monogenic diabetes with strong autosomal dominant family history, onset often before age 25, and negative islet autoantibodies; genetic testing confirms the diagnosis.

Pancreatogenic Diabetes (Type 3c)

Key Distinguishing Feature: Type 3c diabetes arises from exocrine pancreatic disease (e.g., chronic pancreatitis, pancreatectomy), with negative autoantibodies and evidence of pancreatic pathology.

💎

Clinical Pearls

💎

LADA should be suspected in adults with diabetes who are lean, have a personal or family history of autoimmune disease, or have a rapid decline in glycaemic control on oral agents; islet autoantibody testing (particularly GAD65) confirms the diagnosis.

💎

Sulfonylureas are generally avoided in LADA because they stimulate exhausted beta cells and may accelerate the need for insulin; metformin, DPP-4 inhibitors, and GLP-1 receptor agonists are reasonable initial options when beta-cell reserve is preserved.

💎

C-peptide is a useful marker of endogenous insulin secretion; a low or falling C-peptide level signals the need to start or intensify insulin therapy, while a preserved C-peptide supports a trial of non-insulin agents.

💎

The rate of beta-cell decline in LADA is heterogeneous; higher GAD65 titres are associated with faster progression to insulin requirement, whereas lower titres and features of metabolic syndrome may follow a more indolent course.

💎

Patients with LADA require the same complication screening as those with type 1 or type 2 diabetes, including retinal examination, urine albumin-to-creatinine ratio, and foot assessment, because long-term microvascular and cardiovascular risks are substantial.

📝

Example Usage & SOAP

CLINICAL SENTENCE

""52-year-old woman with a 2-year history of diet-controlled diabetes, BMI 23 kg/m², and a history of autoimmune thyroiditis presents with HbA1c rising to 8.4% despite metformin; GAD65 autoantibody is positive and C-peptide is 0.6 nmol/L, consistent with LADA, and basal insulin is initiated.""

IN A SOAP NOTE

S: 52-year-old woman reports increasing fatigue and polyuria over 3 months. O: BMI 23 kg/m², blood pressure 128/78 mmHg, HbA1c 8.4%, fasting glucose 9.8 mmol/L, GAD65 autoantibody positive, C-peptide 0.6 nmol/L, urine albumin-to-creatinine ratio 12 mg/mmol. A: Latent autoimmune diabetes in adults (LADA) with declining beta-cell function; metformin no longer sufficient. P: Start basal insulin (glargine) 10 units subcutaneously once daily, continue metformin, refer to diabetes education, schedule retinal screening and repeat C-peptide in 6 months.

DIFFERENTIAL DIAGNOSIS CONTEXT

Differential for an adult with new diabetes and a lean phenotype: (1) Type 2 diabetes — usually associated with obesity, metabolic syndrome, negative autoantibodies, and preserved C-peptide; (2) Type 1 diabetes — younger age, rapid onset, low C-peptide, and immediate insulin requirement; (3) LADA — adult onset, positive islet autoantibody, and insulin independence for at least 6 months; (4) MODY — strong family history, young onset, negative autoantibodies, and often preserved C-peptide; (5) Pancreatogenic diabetes — history of pancreatitis or pancreatic surgery, negative autoantibodies, and exocrine pancreatic insufficiency.

📊

Classifications & Scoring

SCORING TOOL

LADA Clinical Risk Score (Fourlanos Score)

A five-item clinical score (age <50 years, BMI <25 kg/m², personal history of autoimmune disease, family history of autoimmune disease, and acute hyperglycaemic symptoms at diagnosis) used to identify adults with diabetes who are at higher risk of LADA and warrant autoantibody testing; a score of ≥2 has reasonable sensitivity and specificity for LADA.

Clinical Calculator ↗

📈

Prognosis

SHORT-TERM OUTCOME

In the short term, most patients maintain reasonable glycaemic control without insulin, but beta-cell function is already declining. Deterioration may be accelerated by sulfonylurea use or by intercurrent illness. Regular monitoring of HbA1c and C-peptide helps identify the need for treatment intensification.

LONG-TERM PROGNOSIS

Insulin dependence is eventual in most patients, though the time to insulin requirement varies widely (often years). Long-term microvascular and cardiovascular complication risks are substantial and may equal or exceed those of type 2 diabetes, particularly with poorer glycaemic control. Mortality risk is elevated compared with the general population, driven largely by cardiovascular disease.

📚

References & Coding

ICD-10 DIAGNOSTIC CODE

E13.65

LITERATURE CITATIONS & GUIDELINES

[1]Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes. 1993;42(2):359-362. doi:10.2337/diab.42.2.359

[2]Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nat Rev Endocrinol. 2017;13(11):674-686. doi:10.1038/nrendo.2017.99

[3]Hawa MI, Kolb H, Schloot N, et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care. 2013;36(4):908-913. doi:10.2337/dc12-0931

[4]Lundholm M, Zhou K. Latent autoimmune diabetes in adults: a review. Cleve Clin J Med. 2025;92(12):757-763. doi:10.3949/ccjm.92a.25069

MEDICAL DISCLAIMER — This content is intended for educational purposes and qualified healthcare professionals only. Always refer to current clinical diagnostic criteria, institutional protocols, and official guidelines. Medobo is not responsible for clinical decisions made based on this content.